CTLA4 and hepatocellular carcinoma: IPS, IPS−PD1 blocker, IPS−CTLA4 blocker, and IPS–PD1–CTLA4 blocker were significantly higher in the low-risk group, indicating that the riskScore is the representative immunogenicity of TME in HCC.